US pharma giant Moderna announced that preliminary data from the company’s ongoing study proves that the company’s vaccine has shown more than 94% effectiveness.

A week ago, Pfizer Inc had announced their vaccine to have 90% efficacy, as these two vaccines are firmly on course to seek emergency use authorization from the US Food and Drug Administration (FDA) if results hold out in final study results due soon.

The US is working with a portfolio of six vaccines, using three different platform technologies and two candidates from each platform: Messenger RNA, live viral vectors and recombinant protein. Pfizer and Moderna’s vaccines use the messenger RNA platform, Johnson and Johnson and AstraZeneca in partnership with Oxford University are on the live vector path while Novavax and Sanofi/GlaxoSmithKline are building out their vaccine candidates on the recombinant protein platform.